Taking Another GLP-1 Alongside Mounjaro: What the Evidence Says

Step 1: Understand what Mounjaro already does to the GLP-1 pathway

Before asking whether a second GLP-1 medicine can be added, it helps to know what Mounjaro is doing at the receptor level. Tirzepatide (the active molecule in Mounjaro) binds to both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It was designed this way deliberately. That means every Mounjaro dose already delivers a full GLP-1 effect alongside the GIP action that makes it the only dual-agonist weight-loss medicine licensed in the UK. There is a detailed explanation of the mechanism on the Mounjaro and GLP-1 overview page. Adding a second GLP-1 medicine on top of that (semaglutide, liraglutide, or any other) would not add a meaningfully different receptor signal; it would simply pile additional GLP-1 stimulation onto a system that is already saturated. The clinical concern is not just theoretical redundancy. Doubling up on GLP-1 activity significantly raises the likelihood and severity of gastrointestinal side effects: nausea, vomiting, slowed gastric emptying, and dehydration risk. The NHS medicines page for tirzepatide sets out the standard side-effect profile for Mounjaro used alone, combining medicines with the same mechanism would amplify that profile without adding a licensed benefit. No UK clinical guideline or regulatory body endorses dual GLP-1 therapy for weight management.

Step 2: Recognise that switching is a different question, and a legitimate one

Patients often arrive at this question from a practical place: they have been on Wegovy for months, the results have plateaued, or supply has been patchy, and Mounjaro is now the option in front of them. Switching from one GLP-1 to another is not the same as combining them. A transition from semaglutide (Wegovy) to tirzepatide (Mounjaro) is a clinical pathway that prescribers manage regularly. The key considerations are the current dose and how well tolerated it has been, whether a wash-out period is appropriate (typically no specific wash-out is required, but the prescriber assesses overlap), and the correct Mounjaro starting dose for a transfer patient. On dose history specifically: a patient stepping across from a full maintenance dose of one GLP-1 may not need to restart at 2.5mg if the prescriber judges their tolerance is established, but that is precisely the kind of call a clinician makes with your actual records in front of them, not something to decide alone. You can read more about tirzepatide and how the titration schedule works. If you are currently on a GLP-1 medicine and want to transfer to Mounjaro through nume, the consultation process includes a review of your current treatment and evidence of your most recent dose.

Step 3: Know the specific interactions and add-ons that ARE assessed at consultation

Mounjaro does interact with other medicines, just not in the way a second GLP-1 would. The interaction that gets the most clinical attention is with oral contraceptives. Because tirzepatide slows gastric emptying, absorption of the contraceptive pill can be reduced in the early weeks of treatment. The guidance is to use an additional non-oral contraceptive method for the first four weeks of Mounjaro and for four weeks after each dose increase. For women taking HRT, there is a related question about whether transdermal HRT (patches or gels) might be preferable to oral forms; the Mounjaro and HRT page covers that in detail. Other conditions that come up regularly include IBS, gastrointestinal symptoms can overlap, and the prescriber factors that in. Separate from interactions, some patients ask about supplements or other agents alongside Mounjaro; the Mounjaro and NAD page addresses that category. The consistent answer across all of these is that the prescriber reviews your full medicine and supplement list at consultation, nothing is assumed. It is worth keeping Mounjaro in the fridge door, away from the freezer compartment, and reviewing any oral medicines you take with your pharmacist when you start, since timing relative to food and other medicines can matter.

Step 4: What to bring to the consultation if you are already on a GLP-1

If you are currently taking a GLP-1 medicine and want to explore Mounjaro, a few pieces of information make the clinical review more straightforward. Your current medicine name, the dose you are on, and roughly how long you have been at that dose all help the prescriber map the transition. Your most recent weight is also needed, at nume, this is verified on a brief video call as part of the identity and weight-check process. Evidence of the prescription you are currently taking may be requested for transfer patients. The prescriber can then decide whether a direct transition makes clinical sense, what Mounjaro dose to start at, and whether any timing gap between stopping the first medicine and starting the second is appropriate for your situation. For a broader overview of the Mounjaro options and what private treatment looks like, the Mounjaro treatment page is the place to start. Cost context for anyone comparing options is covered on the Eli Lilly UK price change page. When you are ready, a consultation with one of our prescribers is the straightforward next step, there is no waiting list, and reviews happen the same day.